Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects With Treatment Resistant Herpes Simplex Virus Type 1 or 2
Condition: HSV Intervention: Drug: Pritelivir Sponsors: AiCuris Anti-infective Cures AG; Impatients N.V. trading as myTomorrows Available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 6, 2023 Category: Research Source Type: clinical trials
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
Conditions: Head and Neck Cancer; Esophageal Cancer; Otorhinolaryngologic Neoplasms; Ear Cancer; Nose Cancer; Laryngeal Cancer; Pharyngeal Cancer Intervention: Drug: Recombinant oncolytic herpes simplex virus type 1 (R130) Sponsors: Shanghai Yunying Medical Technology; Eye & ENT Hospital of Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2023 Category: Research Source Type: clinical trials